×
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
NASDAQ:APLT

Applied Therapeutics News Headlines

$0.85
+0.09 (+11.22%)
(As of 06/24/2022 04:00 PM ET)
Add
Compare
Today's Range
$0.78
$0.85
50-Day Range
$0.76
$2.06
52-Week Range
$0.74
$25.00
Volume
2.86 million shs
Average Volume
356,510 shs
Market Capitalization
$22.18 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.10
Get Applied Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for APLT and its competitors with MarketBeat's FREE daily newsletter.

APLT Media Mentions By Week

APLT Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

APLT
News Sentiment

0.77

0.38

Average
Medical
News Sentiment

APLT News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

APLT Articles
This Week

6

1

APLT Articles
Average Week



APLT Stock News Headlines Today

SourceHeadline
markets.businessinsider.com logoNasdaq Jumps Over 100 Points; Applied Therapeutics Shares Plummet
markets.businessinsider.com - June 23 at 3:38 PM
seekingalpha.com logoApplied therapeutics stock sinks on pricing $30M equity offering
seekingalpha.com - June 23 at 4:55 AM
finance.yahoo.com logoApplied Therapeutics, Inc. Announces Pricing of $30 Million Public Offering of Common Stock and Warrants
finance.yahoo.com - June 22 at 11:55 PM
marketwatch.com logoApplied Therapeutics Shares Dive 33% on Public Offering
marketwatch.com - June 22 at 6:52 PM
seekingalpha.com logoApplied Therapeutics launches stock offering
seekingalpha.com - June 22 at 6:52 PM
finance.yahoo.com logoApplied Therapeutics, Inc. Announces Public Offering of Common Stock and Warrants
finance.yahoo.com - June 22 at 6:52 PM
MarketBeat logoApplied Therapeutics (NASDAQ:APLT) Downgraded by Zacks Investment Research to Hold
americanbankingnews.com - June 9 at 4:54 AM
marketwatch.com logoApplied Therapeutics Up After EMA Orphan Medicinal Product Designation
marketwatch.com - June 3 at 10:58 AM
seekingalpha.com logoApplied Therapeutics stock rises on orphan drug status in EU for AT-007 for metabolic disorder
seekingalpha.com - June 3 at 10:58 AM
finance.yahoo.com logoApplied Therapeutics Receives Orphan Medicinal Product Designation from the EMA for AT-007 for Treatment of Galactosemia
finance.yahoo.com - June 3 at 10:58 AM
MarketBeat logoApplied Therapeutics (NASDAQ:APLT) Upgraded to Buy at Zacks Investment Research
americanbankingnews.com - June 2 at 5:00 AM
MarketBeat logoApplied Therapeutics (NASDAQ:APLT) Downgraded to Hold at Zacks Investment Research
americanbankingnews.com - June 1 at 3:30 AM
MarketBeat logoShort Interest in Applied Therapeutics, Inc. (NASDAQ:APLT) Declines By 20.0%
americanbankingnews.com - May 31 at 4:14 AM
seekingalpha.com logoApplied Therapeutics GAAP EPS of -$0.88
seekingalpha.com - May 14 at 9:29 PM
finance.yahoo.com logoThe Zacks Analyst Blog Highlights Angion Biomedica, Applied Therapeutics, Bolt Biotherapeutics, Ikena Oncology, and Landos Biopharma
finance.yahoo.com - May 13 at 1:31 PM
finance.yahoo.com logoEditas' (EDIT) EDIT-301 Gets Orphan Drug Tag for Beta Thalassemia
finance.yahoo.com - May 13 at 1:31 PM
finance.yahoo.com logoApplied Therapeutics Reports First Quarter 2022 Financial Results
finance.yahoo.com - May 12 at 9:57 AM
finance.yahoo.com logoApplied Therapeutics to Present Data on AT-007 Treatment in SORD Deficiency at the 2022 Annual Meeting of the Peripheral Nerve Society
finance.yahoo.com - May 5 at 12:37 PM
finance.yahoo.com logoZosano (ZSAN) to Report Q1 Earnings: What's in the Cards?
finance.yahoo.com - April 28 at 1:14 PM
finance.yahoo.com logoApplied Therapeutics to Present at the 43rd Annual Meeting of the Society for Inherited Metabolic Disorders
finance.yahoo.com - April 4 at 9:16 AM
nasdaq.com logoMonday 3/28 Insider Buying Report: APLT, PLCE
nasdaq.com - March 28 at 3:24 PM
seekingalpha.com logoTCR2 Therapeutics leads healthcare gainers; ORIC Pharmaceuticals, Graphite Bio among losers
seekingalpha.com - March 24 at 11:06 PM
finance.yahoo.com logoApplied Therapeutics to Present at the 2022 Annual Clinical Genetics Meeting of the American College of Molecular Genetics and Genomics
finance.yahoo.com - March 16 at 10:22 AM
benzinga.com logoBragar Eagel & Squire, P.C. Is Investigating Verra, Corcept, Core Scientific, and Applied Therapeutics and Encourages Investors to Contact the Firm
benzinga.com - March 14 at 10:18 PM
nasdaq.com logoApplied Therapeutics, Inc. Common Stock (APLT)
nasdaq.com - March 12 at 8:33 PM
seekingalpha.com logoApplied Therapeutics GAAP EPS of -$4.12 beats by $0.31
seekingalpha.com - March 10 at 11:10 AM
finance.yahoo.com logoApplied Therapeutics Reports Fourth Quarter and Year-end 2021 Financial Results
finance.yahoo.com - March 10 at 11:10 AM
benzinga.com logoBragar Eagel & Squire, P.C. Is Investigating Verra and Applied Therapeutics and Encourages Investors to Contact the Firm
benzinga.com - March 9 at 9:49 PM
finance.yahoo.com logoApplied Therapeutics Supports 15th Annual Rare Disease Day
finance.yahoo.com - February 28 at 10:32 AM
morningstar.com logoBragar Eagel & Squire, P.C. Is Investigating Applied Therapeutics, Gatos, Anavex, and Greenidge and Encourages Investors to Contact the Firm
morningstar.com - February 12 at 3:50 AM
finance.yahoo.com logoApplied Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference
finance.yahoo.com - February 10 at 6:25 PM
benzinga.com logoAPPLIED THERAPEUTICS ALERT: Bragar Eagel
benzinga.com - January 18 at 10:59 PM
benzinga.com logoAPLT INVESTIGATION: Hagens Berman, National Trial...
benzinga.com - January 14 at 2:36 PM
marketwatch.com logoApplied Therapeutics Shares Slide on Lead Candidate Delay >APLT
marketwatch.com - January 5 at 6:24 AM
msn.com logoApplied Therapeutics To Hold Filing FDA Application For AT-007 In Rare Metabolic Disorder
msn.com - January 3 at 1:05 PM
msn.com logoWhy Applied Therapeutics Shares Are Falling Today
msn.com - January 3 at 1:05 PM
finance.yahoo.com logoApplied Therapeutics Tanks as Drug Candidate for Rare Disease Faces Delays
finance.yahoo.com - January 3 at 1:05 PM
msn.com logoWhy Applied Therapeutics Stock Is Sliding Today
msn.com - January 3 at 1:05 PM
marketwatch.com logoApplied Therapeutics Delays Plans to Seek FDA Approval of AT-007
marketwatch.com - January 3 at 8:04 AM
finance.yahoo.com logoApplied Therapeutics Provides Regulatory Update on Galactosemia Program
finance.yahoo.com - January 3 at 8:04 AM
finance.yahoo.com logoApplied Therapeutics Announces Initiation of Registrational Phase 2/3 Study of AT-007 in SORD Deficiency
finance.yahoo.com - December 16 at 7:54 AM
nasdaq.com logoHere's What Applied Therapeutics, Inc.'s (NASDAQ:APLT) Shareholder Ownership Structure Looks Like
nasdaq.com - November 18 at 8:01 AM
finance.yahoo.com logoGreat news for Applied Therapeutics, Inc. (NASDAQ:APLT): Insiders acquired stock in large numbers last year
finance.yahoo.com - November 18 at 8:01 AM
finance.yahoo.com logoApplied Therapeutics Reports Third Quarter 2021 Financial Results
finance.yahoo.com - November 12 at 7:49 AM
finance.yahoo.com logoApplied Therapeutics Reports Biomarker Data from Pilot Trial of AT-007 in SORD Deficiency
finance.yahoo.com - October 25 at 9:55 AM
finance.yahoo.com logoApplied Therapeutics Reports Additional Pediatric Biomarker Data from ACTION-Galactosemia Kids
finance.yahoo.com - October 18 at 9:11 AM
finance.yahoo.com logoApplied Therapeutics Inc. (APLT) Upgraded to Buy: Here's Why
finance.yahoo.com - October 6 at 1:40 PM
finance.yahoo.com logoIs Applied Therapeutics (NASDAQ:APLT) Using Debt Sensibly?
finance.yahoo.com - September 17 at 10:16 AM
nasdaq.com logoDoes Applied Therapeutics (NASDAQ:APLT) Have A Healthy Balance Sheet?
nasdaq.com - September 10 at 11:19 PM
finance.yahoo.com logoApplied Therapeutics Stock Drops On Delayed NDA Submission For Its Lead Candidate
finance.yahoo.com - September 9 at 3:54 PM
Get Applied Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for APLT and its competitors with MarketBeat's FREE daily newsletter.

This page (NASDAQ:APLT) was last updated on 6/24/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.